Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings Corp is experiencing robust growth in its core exome and genome revenue, reporting a remarkable 65% year-over-year increase, which contributed to an 11% beat on topline results and also exceeded bottom-line expectations. The company's strategic shift towards exome and genome testing has led to a significant improvement in average selling prices (ASPs), which rose by 23% year-over-year to $3,850 per test, bolstered by a favorable mix-shift towards higher-margin tests. Additionally, GeneDx has adjusted its 2025 revenue guidance upward to a range of $425-428 million, reflecting a solid growth trajectory of 39-40% year-over-year, underpinned by a 33% increase in core testing volume year-over-year.

Bears say

GeneDx Holdings Corp is facing a negative outlook primarily due to its anticipated cash burn of approximately $2 million per quarter and high denial rates for its tests, which stand at 45% in Q3 2024 despite contracts with around 80% of health plans. The company's reliance on third-party payers for adequate reimbursement poses a significant risk, as any alterations in reimbursement schedules or failure to meet compliance requirements could severely impact its commercial viability. Additionally, operational challenges related to maintaining a consistent supply of sequencers and materials, as well as disruptions in data and workflow services, further threaten GeneDx's financial health and overall results of operations.

WGS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 7 analysts, WGS has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $140.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $140.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.